scopolamine butylbromide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	458	7182-53-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: buscopan scopolamine butyl hydroxide scopolamine butylbromide hyoscine butylbromide butylscopolamine butylscopolammonium butylscopolamine bromide n-butylscopolammonium n-butylscopolammonium bromide	Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract. Molecular weight: 360.47 Formula: C21H30NO4 CLOGP: -1.09 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 59.06 ALOGS: -5.29 ROTB: 8

Molecule

Description

Molfile Inchi Smiles

Synonyms:

buscopan
scopolamine butyl hydroxide
scopolamine butylbromide
hyoscine butylbromide
butylscopolamine
butylscopolammonium
butylscopolamine bromide
n-butylscopolammonium
n-butylscopolammonium bromide

Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract.

Molecular weight: 360.47
Formula: C21H30NO4
CLOGP: -1.09
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 59.06
ALOGS: -5.29
ROTB: 8

Drug dosage:

Dose	Unit	Route
60	mg	O
60	mg	P
60	mg	R

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.69 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	1 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1951	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abdominal pain	147.11	15.78	195	8926	293261	63186640
Constipation	63.67	15.78	115	9006	224828	63255073
Swelling face	53.07	15.78	55	9066	63420	63416481
Swollen tongue	50.35	15.78	41	9080	34759	63445142
Angioedema	46.41	15.78	45	9076	47920	63431981
Lymphoedema	44.22	15.78	25	9096	11667	63468234
Hydronephrosis	43.60	15.78	24	9097	10638	63469263
Dysphonia	34.05	15.78	38	9083	47576	63432325
Aphonia	34.01	15.78	20	9101	10043	63469858
Vomiting	33.70	15.78	164	8957	559453	62920448
Diarrhoea	31.21	15.78	192	8929	715174	62764727
Infective exacerbation of chronic obstructive airways disease	30.33	15.78	10	9111	1247	63478654
Lip swelling	29.77	15.78	29	9092	31034	63448867
Naevus haemorrhage	28.61	15.78	6	9115	125	63479776
Colitis ulcerative	28.13	15.78	26	9095	26065	63453836
Acarodermatitis	27.68	15.78	9	9112	1074	63478827
Drug ineffective for unapproved indication	27.53	15.78	29	9092	34034	63445867
Obstructive pancreatitis	26.29	15.78	7	9114	416	63479485
Purulent discharge	26.12	15.78	13	9108	4693	63475208
Chemical burns of eye	24.80	15.78	5	9116	85	63479816
Adrenocortical insufficiency acute	23.72	15.78	9	9112	1689	63478212
Essential tremor	23.64	15.78	8	9113	1080	63478821
Colitis	22.26	15.78	31	9090	48497	63431404
Arthropod bite	22.19	15.78	14	9107	7964	63471937
Bowel movement irregularity	21.94	15.78	12	9109	5252	63474649
Metastatic gastric cancer	21.63	15.78	5	9116	165	63479736
Skin warm	21.49	15.78	12	9109	5464	63474437
Hepatitis E	21.43	15.78	8	9113	1436	63478465
Arthropathy	21.25	15.78	4	9117	234788	63245113
Subcutaneous abscess	21.25	15.78	12	9109	5584	63474317
Urinary tract infection	19.93	15.78	83	9038	264601	63215300
Enterocolitis	19.91	15.78	13	9108	7845	63472056
Perforation	19.20	15.78	7	9114	1176	63478725
Systemic lupus erythematosus	17.99	15.78	4	9117	208914	63270987
Intestinal obstruction	17.67	15.78	22	9099	30877	63449024
Malaise	17.64	15.78	111	9010	415843	63064058
Encephalopathy neonatal	17.57	15.78	3	9118	19	63479882
Oligohydramnios	17.28	15.78	11	9110	6355	63473546
Pharyngeal swelling	17.22	15.78	11	9110	6393	63473508
Contraindicated product administered	17.14	15.78	5	9116	217643	63262258
Off label use	16.86	15.78	159	8962	674303	62805598
Drug diversion	16.85	15.78	6	9115	942	63478959
Product substitution error	16.74	15.78	3	9118	26	63479875
Glossodynia	16.28	15.78	3	9118	178873	63301028
Anal skin tags	16.07	15.78	5	9116	518	63479383
Pancreatitis haemorrhagic	15.97	15.78	5	9116	528	63479373
Vulvovaginal swelling	15.81	15.78	5	9116	546	63479355

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abdominal pain	54.85	20.21	77	3675	163541	34789638
Pancreatic neoplasm	41.10	20.21	11	3741	897	34952282
Genitalia external ambiguous	38.25	20.21	8	3744	223	34952956
Congenital bladder anomaly	36.63	20.21	8	3744	275	34952904
Foetal hypokinesia	34.20	20.21	8	3744	376	34952803
Neonatal respiratory depression	33.39	20.21	8	3744	417	34952762
Anomaly of external ear congenital	31.08	20.21	6	3746	110	34953069
Vomiting	30.76	20.21	76	3676	247545	34705634
External auditory canal atresia	28.23	20.21	6	3746	181	34952998
Foetal exposure during pregnancy	28.12	20.21	27	3725	38074	34915105
Lung adenocarcinoma	26.62	20.21	12	3740	4659	34948520
Hypomagnesaemia	25.25	20.21	20	3732	21831	34931348
Tumour invasion	25.17	20.21	6	3746	306	34952873
Decubitus ulcer	24.54	20.21	14	3738	8907	34944272
Diarrhoea	22.66	20.21	92	3660	389820	34563359
Intercepted product storage error	21.60	20.21	5	3747	224	34952955
Atrial septal defect	21.41	20.21	12	3740	7380	34945799

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abdominal pain	176.91	14.93	253	11763	389316	79343056
Constipation	71.86	14.93	142	11874	282908	79449464
Swollen tongue	61.23	14.93	51	11965	42519	79689853
Diarrhoea	54.59	14.93	269	11747	880220	78852152
Vomiting	51.31	14.93	217	11799	665611	79066761
Swelling face	49.01	14.93	57	11959	71155	79661217
Lymphoedema	34.12	14.93	22	11994	12391	79719981
Malaise	33.34	14.93	154	11862	489715	79242657
Aphonia	32.67	14.93	20	11996	10292	79722080
Pancreatic neoplasm	32.14	14.93	11	12005	1465	79730907
Dysphonia	31.79	14.93	41	11975	56831	79675541
Hydronephrosis	31.72	14.93	24	11992	17430	79714942
Enterocolitis	30.99	14.93	22	11994	14490	79717882
Naevus haemorrhage	28.32	14.93	6	12010	125	79732247
Angioedema	28.07	14.93	45	11971	75990	79656382
Colitis	27.91	14.93	44	11972	73263	79659109
Intestinal obstruction	27.22	14.93	33	11983	42987	79689385
Lip swelling	26.89	14.93	32	11984	40879	79691493
Acarodermatitis	25.01	14.93	9	12007	1389	79730983
Urinary tract infection	23.82	14.93	93	11923	274419	79457953
Chemical burns of eye	23.01	14.93	5	12011	118	79732254
Levator syndrome	22.65	14.93	4	12012	30	79732342
Purulent discharge	22.49	14.93	13	12003	6026	79726346
Infective exacerbation of chronic obstructive airways disease	22.14	14.93	10	12006	2774	79729598
Metastatic gastric cancer	22.10	14.93	6	12010	366	79732006
Tumour invasion	21.67	14.93	6	12010	394	79731978
Colitis ulcerative	20.92	14.93	26	11990	34716	79697656
Arthropod bite	20.81	14.93	14	12002	8457	79723915
Lower respiratory tract infection	20.60	14.93	54	11962	129166	79603206
Essential tremor	20.48	14.93	8	12008	1547	79730825
Abdominal pain upper	20.37	14.93	77	11939	223742	79508630
Intercepted product storage error	19.23	14.93	5	12011	258	79732114
Nephrolithiasis	18.93	14.93	31	11985	53260	79679112
Skin warm	18.83	14.93	12	12004	6620	79725752
Nausea	18.67	14.93	223	11793	956973	78775399
Perforation	17.60	14.93	7	12009	1419	79730953
Pharyngeal swelling	17.17	14.93	12	12004	7707	79724665
Arthropathy	17.15	14.93	3	12013	177108	79555264
Lung adenocarcinoma	16.97	14.93	12	12004	7852	79724520
Vulvovaginal swelling	16.97	14.93	5	12011	410	79731962
Decubitus ulcer	16.97	14.93	16	12000	15671	79716701
Subcutaneous abscess	16.86	14.93	12	12004	7937	79724435
Metastases to oesophagus	16.04	14.93	3	12013	32	79732340
Myocardial infarction	16.02	14.93	4	12012	184125	79548247
Administration site swelling	15.91	14.93	5	12011	510	79731862
Adrenocortical insufficiency acute	15.33	14.93	8	12008	3035	79729337
Hepatitis alcoholic	15.00	14.93	5	12011	615	79731757
Skin infection	14.94	14.93	16	12000	18229	79714143

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A03BB01	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS BELLADONNA AND DERIVATIVES, PLAIN Belladonna alkaloids, semisynthetic, quaternary ammonium compounds
ATC	A03DB04	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ANTISPASMODICS IN COMBINATION WITH ANALGESICS Belladonna and derivatives in combination with analgesics
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D010276	Parasympatholytics
MeSH PA	D018373	Peripheral Nervous System Agents
CHEBI has role	CHEBI:48876	muscarinic antagonists
CHEBI has role	CHEBI:53784	antispasmodics

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Gastric spasm	indication	196754001

🐶 Veterinary Drug Use

Species	Use	Relation
Horses	Abdominal pain (colic) associated with spasmodic colic	Indication
Horses	Flatulent colic	Indication
Horses	Simple impactions	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Buscopan Injectable Solution	Boehringer lngelheim Animal Health USA Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.24	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Bioact source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN	WOMBAT-PK

External reference:

ID	Source
149-64-4	SECONDARY_CAS_RN
1085787	RXNORM
C0006519	UMLSCUI
CHEBI:32123	CHEBI
CHEMBL1256901	ChEMBL_ID
6852391	PUBCHEM_CID
CHEMBL1618102	ChEMBL_ID
DB09300	DRUGBANK_ID
1156229000	SNOMEDCT_US
395739004	SNOMEDCT_US
D002086	MESH_DESCRIPTOR_UI
2Z3E1OF81V	UNII
003459	NDDF

Pharmaceutical products:

None